MicroRNA‐122 can be measured in capillary blood which facilitates point‐of‐care testing for drug‐induced liver injury

• Published in: British journal of clinical pharmacology Vol. 83; no. 9; pp. 2027 - 2033
• Main Authors: Vliegenthart, A. D. Bastiaan, Berends, Cécile, Potter, Carmelita M. J., Kersaudy‐Kerhoas, Maiwenn, Dear, James W.
• Format: Journal Article
• Language: English
• Published: England John Wiley and Sons Inc 01.09.2017
• Subjects: Adult; Aged; Aged, 80 and over; Biomarkers - blood; Blood Specimen Collection - methods; Capillaries - chemistry; Chemical and Drug Induced Liver Injury - blood; Female; finger prick; Healthy Volunteers; Human Toxicology; Humans; liver toxicity; Male; microRNA; MicroRNAs - analysis; MicroRNAs - blood; Middle Aged; miR‐122; Point-of-Care Testing; point‐of‐care; Sensitivity and Specificity; Young Adult; microRNA; liver toxicity; finger prick; point-of-care; miR-122

Aims Liver‐enriched microRNA‐122 (miR‐122) is a novel circulating biomarker for drug‐induced liver injury (DILI). To date, miR‐122 has been measured in serum or plasma venous samples. If miR‐122 could be measured in capillary blood obtained from a finger prick it would facilitate point‐of‐care testi...